Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Xeris Pharmaceuticals Inc

Healthcare US XERS

5.82USD
0.22(3.93%)

Last update at 2026-03-10T20:00:00Z

Day Range

5.545.87
LowHigh

52 Week Range

1.463.26
LowHigh

Fundamentals

  • Previous Close 5.60
  • Market Cap284.65M
  • Volume1879612
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-32.68600M
  • Revenue TTM171.36M
  • Revenue Per Share TTM1.24
  • Gross Profit TTM 87.61M
  • Diluted EPS TTM-0.47

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -96.08400M -122.72500M -91.25000M -126.03800M -60.08000M
Minority interest - - - - -
Net income -94.66000M -122.72500M -91.14000M -125.58000M -60.08000M
Selling general administrative 137.75M 125.72M 73.73M 63.06M 21.11M
Selling and marketing expenses - - - - -
Gross profit 87.61M 36.27M 10.83M 1.12M 2.42M
Reconciled depreciation 12.67M 1.88M 1.47M 1.08M 0.32M
Ebit -81.94000M -115.15600M -83.54600M -122.38000M -58.05100M
Ebitda -71.09700M -114.60600M -80.58100M -119.56700M -57.73100M
Depreciation and amortization 10.84M 0.55M 2.96M 2.81M 0.32M
Non operating income net other - - -7.70400M -3.65800M -
Operating income -81.94000M -115.15600M -83.54600M -122.38000M -59.34400M
Other operating expenses 192.19M 164.75M 103.70M 125.10M 61.81M
Interest expense 15.32M 7.18M 10.66M 7.16M 2.54M
Tax provision -1.42400M 0.00000M -0.11000M -0.45800M -
Interest income 2.58M 0.31M 2.96M 2.81M 1.61M
Net interest income -12.74700M -6.86700M -7.69500M -4.35000M -0.93200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.42400M -0.11000M -0.11000M -0.45800M 1.81M
Total revenue 110.25M 49.59M 20.16M 2.72M 2.46M
Total operating expenses 169.55M 151.43M 94.37M 123.50M 61.77M
Cost of revenue 22.63M 13.32M 9.33M 1.60M 0.04M
Total other income expense net -14.14400M -7.56900M -7.70400M -3.65800M 0.20M
Discontinued operations - - - - -
Net income from continuing ops -94.66000M -122.72500M -91.14000M -125.58000M -60.08000M
Net income applicable to common shares -94.66000M -122.72500M -91.14000M -125.58000M -60.08000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 322.60M 344.52M 304.36M 159.15M 108.99M
Intangible assets 109.76M 3.99M 131.45M - -
Earning assets - - - - -
Other current assets 5.78M 9.29M 4.59M 3.20M 4.12M
Total liab 329.38M 299.33M 209.13M 125.39M 94.55M
Total stockholder equity -6.78200M 45.19M 95.23M 33.76M 14.44M
Deferred long term liab - - - 6.63M 0.40M
Other current liab 80.13M 2.66M 70.12M 25.09M 21.73M
Common stock 0.01M 0.01M 0.01M 0.00600M 0.00300M
Capital stock 0.01M 0.01M 0.01M 0.00600M 0.00300M
Retained earnings -617.02500M -554.77000M -460.11000M -337.38500M -246.24500M
Other liab - 29.24M 42.02M 10.16M 8.91M
Good will 22.86M 120.61M 22.86M - -
Other assets - 4.73M 0.83M 0.23M 0.42M
Cash 67.45M 121.97M 67.27M 37.60M 19.52M
Cash and equivalents - - - - -
Total current liabilities 95.19M 73.62M 79.04M 28.21M 27.34M
Current deferred revenue - 64.78M - - -
Net debt 161.74M 76.09M 20.80M 49.42M 38.79M
Short term debt 3.50M 1.58M 1.58M - -
Short long term debt - - - - -
Short long term debt total 229.19M 198.06M 88.07M 87.02M 58.30M
Other stockholder equity 610.25M 599.97M 555.36M 371.13M 260.63M
Property plant equipment - 9.51M 6.63M 6.71M 7.85M
Total current assets 156.26M 186.82M 142.60M 152.21M 87.48M
Long term investments - - - 0.00000M 13.23M
Net tangible assets - -98.27900M -59.07800M 33.76M 14.44M
Short term investments 5.00M 0.00000M 35.16M 96.19M 56.03M
Net receivables 39.20M 30.83M 17.46M 6.88M 5.64M
Long term debt 190.93M 187.07M 88.07M 87.02M 58.30M
Inventory 38.84M 24.73M 18.12M 8.35M 2.18M
Accounts payable 11.56M 4.61M 8.92M 3.12M 5.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.02500M -0.02300M -0.03100M 0.00600M 0.04M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00600M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -337.40000M -246.20000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.54M 4.73M 0.83M -12.99900M 0.42M
Deferred long term asset charges - - - - -
Non current assets total 166.34M 157.70M 161.76M 6.94M 21.50M
Capital lease obligations 38.26M 10.98M - - -
Long term debt total - - - 87.02M 58.30M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 34.46M 60.58M -101.77300M -102.47200M -68.85100M
Change to liabilities -4.31800M 5.53M -2.48600M 4.74M -1.11000M
Total cashflows from investing activities 34.46M 97.96M -27.40500M -2.38300M -68.26100M
Net borrowings 102.72M 102.72M 94.84M 60.00M 35.00M
Total cash from financing activities 127.47M 27.25M 126.06M 80.53M 128.21M
Change to operating activities -9.99300M 19.98M 7.01M 13.91M 2.72M
Net income -94.66000M -122.72500M -91.14000M -125.58000M -60.08000M
Change in cash 59.04M 29.67M 18.08M -26.19700M 3.67M
Begin period cash flow 67.27M 37.60M 19.52M 45.72M 42.05M
End period cash flow 126.31M 67.27M 37.60M 19.52M 45.72M
Total cash from operating activities -102.89100M -95.53500M -80.55800M -104.34600M -56.27900M
Issuance of capital stock 30.00M 27.00M 65.89M 61.69M 102.76M
Depreciation 12.67M 1.88M 1.47M 1.08M 0.32M
Other cashflows from investing activities - - - -1.27600M -66.75100M
Dividends paid -147.05000M -25.08900M -95.64300M 60.68M -
Change to inventory -7.46500M -7.41800M -5.14300M -2.17600M 4.04M
Change to account receivables -13.37400M -6.23700M -2.18200M -3.05900M -1.67000M
Sale purchase of stock -0.46800M -0.53400M -0.06300M -4.46500M 98.33M
Other cashflows from financing activities 288.49M 50.96M 180.97M 118.99M 29.89M
Change to netincome 12.69M 12.50M 8.27M 6.48M 1.73M
Capital expenditures 0.52M 1.08M 0.38M 1.11M 1.51M
Change receivables - - -2.18200M -4.69300M -1.67000M
Cash flows other operating - - 0.93M -0.96000M -1.58800M
Exchange rate changes - - -0.02200M 0.00200M -
Cash and cash equivalents changes - - 18.08M -26.19700M 3.67M
Change in working capital -35.15000M 11.85M -2.79800M 11.78M 1.61M
Stock based compensation 12.16M 11.38M 8.27M 6.48M 1.73M
Other non cash items 3.52M 0.96M 3.10M 0.95M 0.56M
Free cash flow -103.41500M -96.62000M -80.93500M -105.45300M -57.78900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
XERS
Xeris Pharmaceuticals Inc		 0.22 3.93% 5.82 - - 1.64 3.86 2.60 -17.9655
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Xeris Pharmaceuticals Inc

180 North LaSalle Street, Chicago, IL, United States, 60601

Key Executives

Name Title Year Born
Mr. Paul R. Edick Chairman & CEO 1956
Mr. John P. Shannon Pres & COO 1962
Ms. Beth P. Hecht J.D. Chief Legal Officer & Corp. Sec. 1964
Dr. Steven J. Prestrelski MBA, Ph.D. Co-Founder & Chief Scientific Officer 1964
Mr. Steven M. Pieper Chief Financial Officer 1977
Ms. Allison Wey Sr. VP of Investor Relations & Corp. Communications NA
Dr. Kenneth E. Johnson Pharm. D., Pharm.D. Sr. VP of Global Devel. & Medical Affairs 1963
Mr. Kevin McCulloch Chief Commercial Officer NA
Mr. John P. Shannon President & COO 1962
Ms. Beth P. Hecht J.D. Chief Legal Officer & Corporate Secretary 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.